ABSTRACT
In the last decade, with the advent of positron emission tomography (PET), nuclear medicine has emerged as an important tool in the diagnosis, staging and treatment evaluation of cancer. With regard to lung cancer, it is valuable in assessing primary, nodal, and extrathoracic disease. While computed tomography (CT) and magnetic resonance imaging (MRI) provide good spatial resolution and anatomical detail, nuclear medicine obtains functional and physiological information in the assessment of cancer.
